GlassScriptPhysician profile
Curtis C Schmidt
NPI 1891836540
$4,387.36
in general payments reported to CMS, 2019-2025
27 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $113 · 2021: $475 · 2022: $484 · 2023: $1,092 · 2024: $1,011 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.90 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.18 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Johnson & Johnson Vision Care, INC. | $461.93 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $400.04 | 2020-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| Glaukos Corporation | $399.94 | 2023-2024 | Idose, Istent Infinite Trabecular Micro Bypass System |
| Tarsus Pharmaceuticals, INC. | $351.48 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $321.16 | 2022-2025 | Vyzulta, Miebo, Envista Mx60 Iol |
| Allergan, INC. | $281.26 | 2019-2022 | |
| Dompe US, INC. | $182.75 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $178.65 | 2020-2021 | |
| Notal Vision, INC. | $173.72 | 2024-2025 | Foresee Home |
| Astellas Pharma US INC | $133.99 | 2023 | Izervay |
| Aerie Pharmaceuticals, INC. | $126.73 | 2019-2021 | |
| Argenx US, INC. | $110.93 | 2025 | |
| Mallinckrodt Hospital Products INC. | $95.55 | 2023-2025 | Acthar |
| Harrow Eye, LLC | $67.21 | 2025 | Vevye |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.80 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $57.96 | 2022-2025 | |
| Sight Sciences, INC. | $56.53 | 2022-2025 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $45.73 | 2023-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Eyevance Pharmaceuticals LLC | $41.00 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $34.79 | 2021 | |
| Oyster Point Pharma, INC. | $30.46 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $30.33 | 2021-2024 | |
| Omeros Corporation | $19.31 | 2019 | |
| Shire North American Group INC | $16.62 | 2019 | |
| Thea Pharma INC. | $16.46 | 2025 | Iyuzeh |
| Eyepoint US, INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.